Expanding therapeutic opportunities for progressive uterine cancer: clinical experience

The incidence of uterine cancer in Russia increased by 28.8 % over the last 10 years. This trend is partly associated with an increasing prevalence of overweight and aging of the female population. Despite the fact that uterine cancer is limited to the uterine body in 84 % of cases, searching for new treatment regimens for patients with progressive disease is still relevant because of their poor outcomes of chemotherapy and high mortality among patients with stage III– IV cancer.

The aim of this study was to present our own view on the effectiveness of lenvatinib + pembrolizumab in patients with advanced or recurrent endometrial cancer on the basis of international and own experience.

The international experience with lenvatinib + pembrolizumab for advanced endometrial cancer without high microsatellite instability or impairments of DNA repair mechanisms after disease progression following previous systemic therapy showed their efficacy (38.3 %), while the effect lasting more than 6 months was observed in 69 % of cases. We report two cases of progressive uterine cancer in patients who developed complete clinical remission and demonstrated good tolerability of the therapy.

1. Malignant tumors (n Russia in 2020 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow, 2021. (In Russ.).

2. Connor E., Rose P. Managementstrategies for recurrent endometrial cancer. Expert Rev Anticancer Ther 2018;18(9):873–85. DOI: 10.1080/14737140.2018.1491311.

3. Binnewies M., Roberts E.W., Kersten K. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018;24(5):541–50. DOI: 10.1038/s41591-018-0014-x.

4. Soumerai T.E., Donoghue M.T., Bandlamudi C. et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer Clin Cancer Res 2018;24:5939–47. DOI:10.1158/1078-0432.CCR-18-0412.

5. Hedhli N., Russell K.S. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev 2011;7(4):221–33. DOI: 10.2174/157340311799960636.

6. Taylor M.H., Lee C.H., Makker V. et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 2020;38:1154–63. DOI: 10.1200/JCO.19.01598.

7. Makker V., Taylor M.H., Aghajanian C. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020;38:2981–92. DOI: 10.1200/JCO.19.02627.

8. Lorusso D., Colombo N., Herraez A.C. et al. Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC). J Clin Oncol 2021;39(Suppl 15):5570.

9. Miller D., Filiaci V., Fleming G. et al. Late-breaking abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012;125:771.

10. Hong D.S., Kurzrock R., Wheler J.J. et al. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res 2015;21:4801–10.

11. Pandey A.K., Singhi E.K., Arroyo J.P.et al. Mechanisms of VEGF inhibitorassociated hypertension and vascular disease. Hypertension 2018;71:e1–e8. DOI:10.1161/HYPERTENSIONAHA.117.10271.

12. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) (published correction appears in Eur Heart J 2016). Eur Heart J 2016;37(36):2768–801.

13. Marth C., Vulsteke C., Jesus Rubio Pérez M. et al. ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer. J Clin Oncol 2019;37(15 Suppl):TPS4152. DOI: 10.1200/JCO.2019.37.15_suppl.TPS4152.